Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662427 | 0.87 | ADRB1 (0.49) | ALOX5ALDH1A1ADRB1KDM4ETSHR | |
| SCHEMBL8416187 | 0.71 | GAA (0.48) | KEAP1MAPK1GAANPC1NPSR1 | |
| SCHEMBL10446112 | 0.70 | KEAP1 (0.41) | KEAP1MAPK1GAANPC1ALDH1A1 | |
| SCHEMBL27550057 | 0.69 | KEAP1 (0.43) | KEAP1MAPK1GAANPC1ALDH1A1 | |
| SCHEMBL1867030 | 0.68 | ALOX5 (0.59) | ALOX5GAANPSR1ALDH1A1MAPT | |
| SCHEMBL1867028 | 0.68 | ALOX5 (0.59) | ALOX5GAANPSR1ALDH1A1MAPT | |
| SCHEMBL5320399 | 0.68 | ALOX5 (0.59) | ALOX5GAANPSR1ALDH1A1MAPT | |
| SCHEMBL89676 | 0.68 | ALOX5 (0.59) | ALOX5GAANPSR1ALDH1A1MAPT | |
| SCHEMBL339368 | 0.68 | ALOX5 (0.60) | ALOX5GAANPSR1MAPTL3MBTL1 | |
| SCHEMBL1919570 | 0.68 | ALOX5 (0.59) | ALOX5GAANPSR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349961-B | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | 西奈山伊坎医学院 | 2022-02-18 | — | — | CN | disclosed |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| CN-108349961-A | Heterocycle is limited tricyclic sulfonamide as antitumor and anticancer agent | 西奈山伊坎医学院 | 2018-07-31 | — | — | CN | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | ALOX5 4631/4885KEAP1 1203/4885MAPK1 2706/4885 |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | ALOX5 4631/4885KEAP1 1203/4885MAPK1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.